Kathleen Squires, MD; Anton L. Pozniak, MD; Gerald Pierone, MD; Corklin R. Steinhart, MD, PhD; Daniel Berger, MD; Nicholaos C. Bellos, MD; Stephen L. Becker, MD; Michael Wulfsohn, MD, PhD; Michael D. Miller, PhD; John J. Toole, MD, PhD; Dion F. Coakley, PharmD; Andrew Cheng, MD, PhD; Study 907 Team*
Presented in part at the 6th International Congress on AIDS in Asia and the Pacific, Melbourne, Australia, 5–10 October 2001; the 8th European Conference on Clinical Aspects and Treatment of HIV Infection, European AIDS Clinical Society, Athens, Greece, 28–31 October 2001; the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Chicago, Illinois, 16–19 December 2001; the 9th Conference on Retroviruses and Opportunistic Infections, Foundation for Retrovirology and Human Health, Seattle, Washington, 24–28 February 2002; and the 14th International AIDS Conference, International AIDS Society, Barcelona, Spain, 7–12 July 2002.
Acknowledgments: The authors gratefully acknowledge the contributions of all the study site personnel and patients who participated in this study.
Grant Support: By Gilead Sciences, Foster City, California.
Potential Financial Conflicts of Interest:Employment: M. Wulfsohn (Gilead Sciences), M.D. Miller (Gilead Sciences), J.J. Toole (Gilead Sciences), D.F. Coakley (Gilead Sciences), A. Cheng (Gilead Sciences); Consultancies: K. Squires (Gilead Sciences), G. Pierone, D. Berger (Gilead Sciences), S.L. Becker; Honoraria: K. Squires (Gilead Sciences), G. Pierone, D. Berger (Gilead Sciences), S.L. Becker; Stock ownership: D. Berger (Gilead Sciences), M. Wulfsohn (Gilead Sciences), M.D. Miller (Gilead Sciences), J.J. Toole, D.F. Coakley (Gilead Sciences), A. Cheng (Gilead Sciences); Grants received: K. Squires, G. Pierone, S.L. Becker; Grants pending: K. Squires; Other: A.L. Pozniak.
Requests for Single Reprints: Andrew Cheng, MD, PhD, 333 Lakeside Drive, Foster City, CA 94404.
Current Author Addresses: Dr. Squires: LAC + USC Medical Center, 1300 North Mission Road, Room 352, Los Angeles, CA 90033.
Dr. Pozniak: St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW109TH, United Kingdom.
Dr. Pierone: 3755 7th Terrace, Suite 302A, Vero Beach, FL 32960.
Dr. Steinhart: Mercy Professional Building, 3661 South Miami Avenue, Suite 806, Miami, FL 33133-4231.
Dr. Berger: 2835 North Sheffield Avenue, Suite 104, Chicago, IL 60657.
Dr. Bellos: 3801 Gaston Avenue, Suite 300, Dallas, TX 75246.
Dr. Becker: 2351 Clay Street, Suite 512, San Francisco, CA 94115.
Drs. Wulfsohn, Miller, Toole, Coakley, and Cheng: 333 Lakeside Drive, Foster City, CA 94404.
Author Contributions: Conception and design: M. Wulfsohn, M.D. Miller.
Analysis and interpretation of the data: K. Squires, M. Wulfsohn, M.D. Miller, J.J. Toole, D.F. Coakley, A. Cheng.
Drafting of the article: K. Squires, A.L. Pozniak, G. Pierone, M.D. Miller, D.F. Coakley, A. Cheng.
Critical revision of the article for important intellectual content: K. Squires, A.L. Pozniak, G. Pierone, C.R. Steinhart, D. Berger, N.C. Bellos, S.L. Becker, M. Wulfsohn, M.D. Miller, J.J. Toole, D.F. Coakley, A. Cheng.
Final approval of the article: K. Squires, A.L. Pozniak, G. Pierone, C.R. Steinhart, D. Berger, N.C. Bellos, S.L. Becker, M. Wulfsohn, M.D. Miller, J.J. Toole, D.F. Coakley, A. Cheng.
Provision of study materials or patients: K. Squires, A.L. Pozniak, G. Pierone, C.R. Steinhart, D. Berger, N.C. Bellos, S.L. Becker.
Statistical expertise: M. Wulfsohn.
Collection and assembly of data: G. Pierone, J.J. Toole.
Squires K, Pozniak AL, Pierone G, Steinhart CR, Berger D, Bellos NC, et al. Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial. Ann Intern Med. 2003;139:313-320. doi: 10.7326/0003-4819-139-5_Part_1-200309020-00006
Download citation file:
Published: Ann Intern Med. 2003;139(5_Part_1):313-320.
Combination antiretroviral therapy has decreased mortality rates for patients with HIV-1 infection (1-2). Suppression of HIV-1 viral load has been shown to be highly predictive of slower clinical disease progression (3). However, the clinical utility of a combination antiretroviral regimen typically wanes, often because of one or more factors such as drug resistance or poor adherence (4). These factors are even more important for patients who have previously used antiretroviral drugs. This difficult-to-treat population has limited treatment options and often experiences drug-related adverse effects due to previous antiretroviral therapy regimens (5-7). Given these limitations, novel potent agents that combine ease of dosing with favorable safety and resistance profiles are needed to increase the long-term durability of combination antiretroviral therapy (8-9). Simplifying HIV treatment regimens using once-daily antiretroviral drugs may improve adherence and therapeutic outcomes (10-11).
Learn more about subscription options.
Register Now for a free account.
Infectious Disease, HIV, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only